1. Taiwan Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Apex Biotechnology Corp.

Apex Biotechnology Corp.

TTWSE:1733
29.60
TWD
-0.25
(-0.84%)
1.90EPS
15.40P/E
2.93BMarket Cap
Nov 05Next Earn
Apex Biotechnology Corp.
TWSE:1733
(Taiwan Stock Exchange)

Recent

price

29.60

P/E

ratio

15.40

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
TWD
18.26
19.64
20.94
18.56
18.16
18.74
17.72
18
20.5
22.01
20.15
21.37
22.45
16.77
18.53
19.46
18.67
Revenue per Share
4.74
5.51
5.41
3.77
2.77
2.66
0.03
0.86
0.95
1.14
0.95
2.03
1.82
1.16
1.28
1.63
1.9
Basic EPS, GAAP
3.18
2.08
0.88
2.41
2.05
4.52
2.61
0.44
-0.08
4.06
2.33
1.54
-0.14
2.06
3.04
1.41
2.6
Free Cash Flow per Basic Share
3.09
4.2
4.93
4.5
3.3
2.5
2.24
1.5
1.5
0.85
1.1
1.1
1.3
1.4
1.1
1.2
- -
Dividend per Share
17.01
18.02
20.18
19.48
18.96
19.43
17.37
16.69
16.47
16.77
16.56
17.54
18.18
17.97
18.25
18.71
18.6
Book Value per Share
16.84
17.84
20.04
19.22
18.65
19.14
17.11
13.74
14.52
15.2
15.26
16.47
17.49
17.53
17.85
18.35
18.26
Tangible Book Value per Share
96
96
97
99
99
99
100
100
100
100
100
100
100
100
100
100
100
Basic Weighted Avg Shares
1,750
1,876
2,026
1,829
1,789
1,847
1,763
1,795
2,044
2,199
2,005
2,132
2,244
1,677
1,852
1,945
1,867
Sales/Revenue/Turnover
32.81
29.72
29.77
19.08
16.18
16.28
13.94
8.97
11.12
9.26
5.13
9.45
7.87
8.56
6.94
7.97
9.1
Operating Margin (%)
70
84
89
98
115
112
103
110
106
116
105
96
94
76
65
61
59
Depreciation Expense
454
527
523
371
273
262
3
86
95
114
95
202
182
116
128
163
190
Net Income, GAAP
14.8
11.58
12.28
13.03
15.66
15.98
94.32
26.41
41.95
30.66
14.45
- -
9.08
17.91
16.34
14.14
13
Effective Tax Rate (%)
25.94
28.07
25.82
20.29
15.28
14.17
0.18
4.77
4.65
5.18
4.73
9.49
8.1
6.91
6.91
8.38
10.19
Profit Margin (%)
1,040
1,158
1,479
1,064
680
1,184
1,188
580
1,080
1,156
801
974
1,084
1,123
1,165
1,242
1,243
Working Capital
- -
- -
384
390
- -
346
334
- -
388
508
118
128
123
116
114
102
101
LT Debt
1,630
1,727
1,990
1,921
1,866
1,930
1,732
1,665
1,644
1,677
1,646
1,754
1,818
1,797
1,824
1,870
1,860
Total Equity
29.27
27.73
24.67
12.42
10.28
10.76
0.61
5.22
5.81
6.1
3.75
- -
7.58
5.64
5.32
5.95
7.53
Return on Invested Capital (%)
27.72
30.25
25.03
15.76
12.16
11.67
0.17
4.28
4.64
5.44
4.55
- -
8.99
5.91
6.6
8.26
9.78
Return on Capital (%)
29.28
31.37
28.16
19
14.44
13.79
0.17
5.04
5.75
6.86
5.71
11.9
10.18
6.41
7.07
8.82
10.43
Return on Common Equity (%)

Capital Structure

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
47
56
43
LT Borrowings
- -
- -
- -
LT Finance Leases
102
102
101
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
100
100
100
Market Capitalization
3,043
2,924
2,929

Working Capital

TWD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
1,674
1,759
1,832
Cash, Cash Equivalents & STI
644
668
815
Accounts Receivable, Net
438
499
399
Inventories
562
559
593
Total Current Liabilities
432
561
589
Payables & Accruals
- -
- -
- -
ST Debt
47
56
43
Deferred Revenue
- -
- -
- -

Growth Rates

TWD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-0.21%
2.62%
2.54%
Free Cash Flow
-740%
-352.14%
-53.58%
Net Income, GAAP
260.96%
20.94%
27.26%
Sales/Revenue/Turnover
1.17%
0.35%
5%
Total Cash Common Dividend
- -
2.73%
9.09%

Quarterly Revenue

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
451
438
510
454
1,852
2025
559
510
437
439
1,945
2026
520
471
- -
- -
- -

Quarterly Earnings Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.29
0.27
0.33
0.39
1.28
2025
0.62
0.29
0.22
0.5
1.63
2026
0.81
0.37
- -
- -
- -

Quarterly Dividends Per Share

TWD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
1.1
2025
- -
- -
- -
- -
1.2
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Apex Biotechnology Corp. (1733.TW) researches, develops, manufactures, and sells home care medical devices utilizing biosensor technology. The company offers blood glucose monitoring systems, uric acid monitoring systems, hemoglobin monitoring systems, cholesterol monitoring systems, lactate monitoring systems, HbA1C monitoring systems, ketone monitoring systems, coagulation and multifunctional self-testing systems, Hemosmart Gold hemoglobin screening systems, and pesticide residue quick check systems; it also provides care management and tele-health services. Apex Biotechnology operates primarily in the biotechnology and medical care industry, targeting patients, doctors, nurses in hospitals and clinics, and consumers for home diagnostics, with distribution in Taiwan, the Americas, Europe, and Asia. Founded in 1997 and headquartered at No. 7, Li-Hsin 5th Road, Hsinchu Science Park, Hsinchu City, Taiwan, the company maintains manufacturing facilities in Taoyuan, Taiwan, and Suzhou, China, alongside a U.S. subsidiary, Omnis Health LLC in Nashville, Tennessee. Recent developments include steady revenue growth, with consolidated revenues reaching NT$1.51 billion for the first nine months of 2025, reflecting year-over-year increases driven by core diagnostic product demand.